MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamaneurol.2021.5216

Медицинская библиотека · JAMA neurology · 2022

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Jansen Willemijn J, Janssen Olin, Tijms Betty M, Vos Stephanie J B, Ossenkoppele Rik, Visser Pieter Jelle, Amyloid Biomarker Study Group, Aarsland Dag, Alcolea Daniel, Altomare Daniele, von Arnim Christine, Baiardi Simone, Baldeiras Ines, Barthel Henryk, Bateman Randall J, Van Berckel Bart, Binette Alexa Pichet, Blennow Kaj, Boada Merce, Boecker Henning, Bottlaender Michel, den Braber Anouk, Brooks David J, Van Buchem Mark A, Camus Vincent, Carill Jose Manuel, Cerman Jiri, Chen Kewei, Chételat Gaël, Chipi Elena, Cohen Ann D, Daniels Alisha, Delarue Marion, Didic Mira, Drzezga Alexander, Dubois Bruno, Eckerström Marie, Ekblad Laura L, Engelborghs Sebastiaan, Epelbaum Stéphane, Fagan Anne M, Fan Yong, Fladby Tormod, Fleisher Adam S, Van der Flier Wiesje M, Förster Stefan, Fortea Juan, Frederiksen Kristian Steen, Freund-Levi Yvonne, Frings Lars, Frisoni Giovanni B, Fröhlich Lutz, Gabryelewicz Tomasz, Gertz Hermann-Josef, Gill Kiran Dip, Gkatzima Olymbia, Gómez-Tortosa Estrella, Grimmer Timo, Guedj Eric, Habeck Christian G, Hampel Harald, Handels Ron, Hansson Oskar, Hausner Lucrezia, Hellwig Sabine, Heneka Michael T, Herukka Sanna-Kaisa, Hildebrandt Helmut, Hodges John, Hort Jakub, Huang Chin-Chang, Iriondo Ane Juaristi, Itoh Yoshiaki, Ivanoiu Adrian, Jagust William J, Jessen Frank, Johannsen Peter, Johnson Keith A, Kandimalla Ramesh, Kapaki Elisabeth N, Kern Silke, Kilander Lena, Klimkowicz-Mrowiec Aleksandra, Klunk William E, Koglin Norman, Kornhuber Johannes, Kramberger Milica G, Kuo Hung-Chou, Van Laere Koen, Landau Susan M, Landeau Brigitte, Lee Dong Young, de Leon Mony, Leyton Cristian E, Lin Kun-Ju, Lleó Alberto, Löwenmark Malin, Madsen Karine, Maier Wolfgang, Marcusson Jan, Marquié Marta, Martinez-Lage Pablo, Maserejian Nancy, Mattsson Niklas, de Mendonça Alexandre, Meyer Philipp T, Miller Bruce L, Minatani Shinobu, Mintun Mark A, Mok Vincent C T, Molinuevo Jose Luis, Morbelli Silvia Daniela, Morris John C, Mroczko Barbara, Na Duk L, Newberg Andrew, Nobili Flavio, Nordberg Agneta, Olde Rikkert Marcel G M, de Oliveira Catarina Resende, Olivieri Pauline, Orellana Adela, Paraskevas George, Parchi Piero, Pardini Matteo, Parnetti Lucilla, Peters Oliver, Poirier Judes, Popp Julius, Prabhakar Sudesh, Rabinovici Gil D, Ramakers Inez H, Rami Lorena, Reiman Eric M, Rinne Juha O, Rodrigue Karen M, Rodríguez-Rodriguez Eloy, Roe Catherine M, Rosa-Neto Pedro, Rosen Howard J, Rot Uros, Rowe Christopher C, Rüther Eckart, Ruiz Agustín, Sabri Osama, Sakhardande Jayant, Sánchez-Juan Pascual, Sando Sigrid Botne, Santana Isabel, Sarazin Marie, Scheltens Philip, Schröder Johannes, Selnes Per, Seo Sang Won, Silva Dina, Skoog Ingmar, Snyder Peter J, Soininen Hilkka, Sollberger Marc, Sperling Reisa A, Spiru Luisa, Stern Yaakov, Stomrud Erik, Takeda Akitoshi, Teichmann Marc, Teunissen Charlotte E, Thompson Louisa I, Tomassen Jori, Tsolaki Magda, Vandenberghe Rik, Verbeek Marcel M, Verhey Frans R J, Villemagne Victor, Villeneuve Sylvia, Vogelgsang Jonathan, Waldemar Gunhild, Wallin Anders, Wallin Åsa K, Wiltfang Jens, Wolk David A, Yen Tzu-Chen, Zboch Marzena, Zetterberg Henrik

СтатьяПеревод пока не подготовлен

Аннотация

IMPORTANCE

One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design.

OBJECTIVE

To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates.

DESIGN, SETTING, AND

PARTICIPANTS

This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria.

EXPOSURES: Alzheimer disease biomarkers detected on PET or in CSF.

MAIN OUTCOMES AND MEASURES: Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations.

RESULTS

Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P = .04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P = .004), subjective cognitive decline (9%; 95% CI, 3%-15%; P = .005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P = .004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P = .18).

CONCLUSIONS AND RELEVANCE: This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.

Для цитирования: Jansen Willemijn J, Janssen Olin, Tijms Betty M, Vos Stephanie J B, Ossenkoppele Rik, Visser Pieter Jelle, Amyloid Biomarker Study Group, Aarsland Dag, Alcolea Daniel, Altomare Daniele, von Arnim Christine, Baiardi Simone, Baldeiras Ines, Barthel Henryk, Bateman Randall J, Van Berckel Bart, Binette Alexa Pichet, Blennow Kaj, Boada Merce, Boecker Henning, Bottlaender Michel, den Braber Anouk, Brooks David J, Van Buchem Mark A, Camus Vincent, Carill Jose Manuel, Cerman Jiri, Chen Kewei, Chételat Gaël, Chipi Elena, Cohen Ann D, Daniels Alisha, Delarue Marion, Didic Mira, Drzezga Alexander, Dubois Bruno, Eckerström Marie, Ekblad Laura L, Engelborghs Sebastiaan, Epelbaum Stéphane, Fagan Anne M, Fan Yong, Fladby Tormod, Fleisher Adam S, Van der Flier Wiesje M, Förster Stefan, Fortea Juan, Frederiksen Kristian Steen, Freund-Levi Yvonne, Frings Lars, Frisoni Giovanni B, Fröhlich Lutz, Gabryelewicz Tomasz, Gertz Hermann-Josef, Gill Kiran Dip, Gkatzima Olymbia, Gómez-Tortosa Estrella, Grimmer Timo, Guedj Eric, Habeck Christian G, Hampel Harald, Handels Ron, Hansson Oskar, Hausner Lucrezia, Hellwig Sabine, Heneka Michael T, Herukka Sanna-Kaisa, Hildebrandt Helmut, Hodges John, Hort Jakub, Huang Chin-Chang, Iriondo Ane Juaristi, Itoh Yoshiaki, Ivanoiu Adrian, Jagust William J, Jessen Frank, Johannsen Peter, Johnson Keith A, Kandimalla Ramesh, Kapaki Elisabeth N, Kern Silke, Kilander Lena, Klimkowicz-Mrowiec Aleksandra, Klunk William E, Koglin Norman, Kornhuber Johannes, Kramberger Milica G, Kuo Hung-Chou, Van Laere Koen, Landau Susan M, Landeau Brigitte, Lee Dong Young, de Leon Mony, Leyton Cristian E, Lin Kun-Ju, Lleó Alberto, Löwenmark Malin, Madsen Karine, Maier Wolfgang, Marcusson Jan, Marquié Marta, Martinez-Lage Pablo, Maserejian Nancy, Mattsson Niklas, de Mendonça Alexandre, Meyer Philipp T, Miller Bruce L, Minatani Shinobu, Mintun Mark A, Mok Vincent C T, Molinuevo Jose Luis, Morbelli Silvia Daniela, Morris John C, Mroczko Barbara, Na Duk L, Newberg Andrew, Nobili Flavio, Nordberg Agneta, Olde Rikkert Marcel G M, de Oliveira Catarina Resende, Olivieri Pauline, Orellana Adela, Paraskevas George, Parchi Piero, Pardini Matteo, Parnetti Lucilla, Peters Oliver, Poirier Judes, Popp Julius, Prabhakar Sudesh, Rabinovici Gil D, Ramakers Inez H, Rami Lorena, Reiman Eric M, Rinne Juha O, Rodrigue Karen M, Rodríguez-Rodriguez Eloy, Roe Catherine M, Rosa-Neto Pedro, Rosen Howard J, Rot Uros, Rowe Christopher C, Rüther Eckart, Ruiz Agustín, Sabri Osama, Sakhardande Jayant, Sánchez-Juan Pascual, Sando Sigrid Botne, Santana Isabel, Sarazin Marie, Scheltens Philip, Schröder Johannes, Selnes Per, Seo Sang Won, Silva Dina, Skoog Ingmar, Snyder Peter J, Soininen Hilkka, Sollberger Marc, Sperling Reisa A, Spiru Luisa, Stern Yaakov, Stomrud Erik, Takeda Akitoshi, Teichmann Marc, Teunissen Charlotte E, Thompson Louisa I, Tomassen Jori, Tsolaki Magda, Vandenberghe Rik, Verbeek Marcel M, Verhey Frans R J, Villemagne Victor, Villeneuve Sylvia, Vogelgsang Jonathan, Waldemar Gunhild, Wallin Anders, Wallin Åsa K, Wiltfang Jens, Wolk David A, Yen Tzu-Chen, Zboch Marzena, Zetterberg Henrik. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. JAMA neurology. 2022. DOI: 10.1001/jamaneurol.2021.5216.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.